UBS Group
LAB icon

UBS Group’s Standard BioTools LAB Stock Holding History

UBS Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100
Closed -$3K – 9080
2014
Q4 		$3K Buy
+100
New +$2.83K ﹤0.01% 9241

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

UBS Group's LAB Position: Q1 2026 in Review

UBS Group increased its Standard BioTools (LAB) stake by 15% in Q1 2026, buying an estimated $49.3K and bringing the position to 305,122 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #6440.

UBS Group first reported a position in LAB in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.19M in Q3 2021. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • UBS Group held 305,122 shares of Standard BioTools worth $280K as of Q1 2026.
  • UBS Group bought 40,717 Standard BioTools shares in Q1 2026, an estimated $49.3K.
  • Standard BioTools made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6440 holding.
  • UBS Group first reported a position in Standard BioTools in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Standard BioTools position peaked at $5.19M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.